Discrete opioid gene expression impairment in the human fetal brain associated with maternal marijuana use

Pharmacogenomics Journal

Volumn 6, Issue 4, 2006, Pages 255-264

  Wang, X ^a   Dow Edwards, D ^b   Anderson, V ^b   Minkoff, H ^c   Hurd, Y L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c KINGS COUNTY HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MESSENGER RNA; MU OPIATE RECEPTOR; NICOTINE; OPIATE; OPIATE PEPTIDE; PREPRODYNORPHIN; PREPROENKEPHALIN; PROTEIN PRECURSOR; SODIUM CHLORIDE;

ABORTION; ADULT; AGE DISTRIBUTION; AMYGDALOID NUCLEUS; ARTICLE; AUTOPSY; BRAIN; BRAIN CORTEX; BRAIN REGION; CANNABIS ADDICTION; CIGARETTE SMOKING; CLAUSTRUM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONFOUNDING VARIABLE; CONTROLLED STUDY; EMOTIONAL DISORDER; FEMALE; FETUS; FETUS GROWTH; GENE EXPRESSION; GENE EXPRESSION PROFILING; GESTATION PERIOD; HUMAN; HUMAN TISSUE; INSULA; MALE; MULTIPLE REGRESSION; NUCLEOTIDE SEQUENCE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUTAMEN; SEX DIFFERENCE; THALAMUS DORSOMEDIAL NUCLEUS;

ADULT; ALCOHOL DRINKING; DYNORPHINS; ENKEPHALINS; FEMALE; FETUS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GESTATIONAL AGE; HUMANS; IN SITU HYBRIDIZATION; MARIJUANA SMOKING; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSENCEPHALON; PROTEIN PRECURSORS; RECEPTORS, OPIOID; RNA, MESSENGER;

CANNABIS; CANNABIS SATIVA;

EID: 33746485110     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500375     Document Type: Article

References (57)

1. SAMHSA. Results from the 2001 National Household Survey on Drug Abuse. Substance Abuse and Mental Health Service Administration: Rockville, MD, 2002.
2. Chasnoff IJ, McGourty RF, Bailey GW, Hutchins E, Lightfoot SO, Pawson LL et al. The 4P's plus((c)) screen for substance use in pregnancy: clinical application and outcomes. J Perinatol 2005; 25: 368-374.
3. Mato S, Del Olmo E, Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci 2003; 17: 1747-1754.
4. Berrendero F, Garcia-Gil L, Hernandez ML, Romero J, Cebeira M, de Miguel R et al. Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development 1998; 125: 3179-3188.
5. 1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180.
6. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: A general view and latest additions. Br J Pharmacol 2004; 141: 765-774.
7. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-1936.
8. Wang X, Dow-Edwards D, Keller E, Hurd YL. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 2003; 118: 681-694.
9. 1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001; 118: 61-65.
10. Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: Reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 2001; 13: 1816-1824.
11. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002; 22: 1146-1154.
12. 1 receptors by cannabinoids. Eur J Neurosci 1998; 10: 2825-2830.
13. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109: 451-460.
14. Corchero J, Avila MA, Fuentes JA, Manzanares J. Delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci 1997; 61: PL39-PL43.
15. Gerrits MA, Lesscher HB, van Ree JM. Drug dependence and the endogenous opioid system. Eur Neuropsychopharmacol 2003; 13: 424-434.
16. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: Biology and function. Annu Rev Neurosci 1984; 7: 223-255.
17. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73: 953-990.
18. Bailey CP, Connor M. Opioids: Cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 2005; 5: 60-68.
19. Navarro M, Rubio P, de Fonseca FR. Behavioural consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology (Berlin) 1995; 122: 1-14.
20. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol 2000; 22: 325-336.
21. Fried PA. Conceptual issues in behavioral teratology and their application in determining long-term sequelae of prenatal marihuana exposure. J Child Psychol Psychiatry 2002; 43: 81-102.
22. Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL. In utero marijuana exposure associated with abnormal amygdala dopamine D(2) gene expression in the human fetus. Biol Psychiatry 2004; 56: 909-915.
23. Wright A, Walker J. Drugs of abuse in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001; 15: 987-998.
24. Bennett AD. Perinatal substance abuse and the drug-exposed neonate. Adv Nurse Pract 1999; 7: 32-36; quiz 37-38.
25. Mattson SN, Riley EP. A review of the neurobehavioral deficits in children with fetal alcohol syndrome or prenatal exposure to alcohol. Alcohol Clin Exp Res 1998; 22: 279-294.
26. Roebuck TM, Mattson SN, Riley EP. Behavioral and psychosocial profiles of alcohol-exposed children. Alcohol Clin Exp Res 1999; 23: 1070-1076.
27. Goldschmidt L, Richardson GA, Stoffer DS, Geva D, Day NL. Prenatal alcohol exposure and academic achievement at age six: A nonlinear fit. Alcohol Clin Exp Res 1996; 20: 763-770.
28. Wang X, Dow-Edwards D, Keller E, Hurd YL. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 2003; 118: 681-694.
29. Perez-Rosado A, Manzanares J, Fernandez-Ruiz J, Ramos JA. Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: Sex-dependent differences. Brain Res Dev Brain Res 2000; 120: 77-81.
30. Corchero J, Garcia-Gil L, Manzanares J, Fernandez-Ruiz JJ, Fuentes JA, Ramos JA. Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats. Life Sci 1998; 63: 843-850.
31. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res 1998; 55: 126-132.
32. 1-cannabinoid receptors in the caudate-putamen. Brain Res Mol Brain Res 1999; 67: 148-157.
33. Perez-Rosado A, Gomez M, Manzanares J, Ramos JA, Fernandez-Ruiz J. Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Delta(9)-tetrahydrocannabinol. Neurotox Res 2002; 4: 211-218.
34. Vela G, Martin S, Garcia-Gil L, Crespo JA, Ruiz-Gayo M, Javier Fernandez-Ruiz J et al. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res 1998; 807: 101-109.
35. Corchero J, Oliva JM, Garcia-Lecumberri C, Martin S, Ambrosio E, Manzanares J. Repeated administration with Delta9-tetrahydrocannabinol regulates mu-opioid receptor density in the rat brain. Psychopharmacol 2004; 18: 54-58.
36. Rosin A, Lindholm S, Franck J, Georgieva J. Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens. Neurosci Lett 1999; 275: 1-4.
37. Kovacs KM, Szakall I, O'Brien D, Wang R, Vinod KY, Saito M et al. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res 2005; 29: 730-738.
38. Beadles-Bohling AS, Wiren KM. Alteration of kappa-opioid receptor system expression in distinct brain regions of a genetic model of enhanced ethanol withdrawal severity. Brain Res 2005; 1046: 77-89.
39. Holter SM, Henniger MS, Lipkowski AW, Spanagel R. Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats. Psychopharmacology (Berlin) 2000; 153: 93-102.
40. Baer JS, Barr HM, Bookstein FL, Sampson PD, Streissguth AP. Prenatal alcohol exposure and family history of alcoholism in the etiology of adolescent alcohol problems. J Stud Alcohol 1998; 59: 533-543.
41. Mathieu-Kia AM, Besson MJ. Repeated administration of cocaine, nicotine and ethanol: Effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Brain Res Mol Brain Res 1998; 54: 141-151.
42. Fadda P, Tronci S, Colombo G, Fratta W. Differences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats. Alcohol Clin Exp Res 1999; 23: 1296-1305.
43. Pomerleau OF. Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology 1998; 23: 115-130.
44. Mathieu-Kia AM, Kellogg SH, Butelman ER, Kreek MJ. Nicotine addiction: insights from recent animal studies. Psychopharmacology (Berlin) 2002; 162: 102-118.
45. Bodnar RJ, Klein GE. Endogenous opiates and behavior: 2003. Peptides 2004; 25: 2205-2256.
46. Aggleton JP. The contribution of the amygdala to normal and abnormal emotional states. Trends Neurosci 1993; 16: 328-333.
47. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci 1999; 877: 412-438.
48. Fried PA. Behavioral outcomes in preschool and school-age children exposed prenatally to marijuana: A review and speculative interpretation. NIDA Res Monogr 1996; 164: 242-260.
49. Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure. Effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol 2002; 24: 309-320.
50. Willford JA, Richardson GA, Leech SL, Day NL. Verbal and visuospatial learning and memory function in children with moderate prenatal alcohol exposure. Alcohol Clin Exp Res 2004; 28: 497-507.
51. Goldschmidt L, Richardson GA, Cornelius MD, Day NL. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol 2004; 26: 521-532.
52. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol 2001; 23: 1-11.
53. Brana C, Charron G, Aubert I, Carles D, Martin-Negrier ML, Trouette H et al. Ontogeny of the striatal neurons expressing neuropeptide genes in the human fetus and neonate. J Comp Neurol 1995; 360: 488-505.
54. Mailleux P, Verslype M, Preud'homme X, Vanderhaeghen JJ. Activation of multiple transcription factor genes by tetrahydrocannabinol in rat forebrain. Neuroreport 1994; 5: 1265-1268.
55. Casu MA, Pisu C, Sanna A, Tambaro S, Spada GP, Mongeau R et al. Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study. Brain Res 2005; 1048: 41-47.
56. Hurd YL, Suzuki M, Sedvall GC. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J Chem Neuroanat 2001; 22: 127-137.
57. Feess-Higgins A, Larroche J-C. Development of the Human Foetal Brain. An anatomical atlas: Masson, Paris, 1987.